Withdrawal of Medication in Recovered DCM

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Withdrawal of Medication in Recovered DCM

Official Title

Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.

Brief Summary

      Randomized study of medication withdrawal in patients who have recovered LV function in
      Dilated Cardiomyopathy.

Detailed Description

      Importance of the study:

      There is a growing population of patients with dilated cardiomyopathy (DCM) who had recovered
      left ventricular (LV) systolic function on medical therapy. Recent studies have shown a
      favorable clinical course in patients with DCM1-4. The heart failure (HF) guidelines states
      that discontinuation of medical therapy in this group of patients may be considered based on
      expert opinion. The safety of withdrawal of medical therapy needs further studies.


      In Patients with dilated cardiomyopathy (DCM) who had recovery of the LV systolic function to
      a normal EF >50%, medical therapy withdrawal is attainable without Clinical deterioration or
      recurrence of LV systolic dysfunction.


        1. To study the withdrawal of guideline directed medical therapy, specifically
           beta-blockers and ACE/ARB, in patients with DCM after recovery of LV EF.

        2. Correlate the sustained recovery in LVEF after medication discontinuation with specific
           genetic markers of recovery.


      Study design:

      It is a multi-center, non-blinded, randomized Control trial (pilot) comparing withdrawal of
      medical therapy in patients with recovered LVEF (recEF) compared to patients continuing
      medical therapy. Therapeutic changes will occur in a 2:1 randomization at the Royal Victoria
      Hospital, the Montreal General Hospital and the Jewish General Hospital. Patient would be
      recruited from a Heart Function Clinic or the echocardiography lab.


      Patient Selection:

      Patient selection will be conducted through chart review, ECHO lab, as well as the clinical
      visits. The DPS authorization will be requested.

      Informed consent:

      At time of enrolment the study's objective, procedures as well as the risks and benefits will
      be explained to the patient. A consent form will be provided to the patient. In addition, a
      wallet card and a medication discontinuations chart.


      Randomization will be conducted in 2:1 fashion, non-blinded, through a sealed envelop
      randomization system.

      Medical therapy withdrawal:

      Medical therapy withdrawal will be conducted in 2 phases.

      Phase 1:

      This phase involves the withdrawal of the beta-blocker. The patient will be followed for
      signs of deterioration for a period of 6 months following the withdrawal.

      Phase 2:

      If there are no signs of deterioration the ACE/ARB inhibitor will be withdrawn as well. The
      patient will be followed up in 6 month for signs of deterioration. All other medical
      therapies other than beta-blocker and ACE inhibitors will continue until successful
      withdrawal of beta-blockers and ACE inhibitor is achieved.

      Beta-blocker discontinuation:

      The initial tapering off will occur over a 2week period. The beta -blocker will be
      discontinued by the end of the 2nd week.

      For example: Metoprolol 100mg bid to Metoprolol 75mg bid for 5days. Followed by Metoprolol
      50mg bid for 4 days, then Metoprolol 25 mg for 3 days and then completely discontinued.

      ACE/ARB discontinuation:

      The discontinuation of ACE/ARB will be similar to the beta-blockers. The doses will be
      tapered over a two-week period.

      A supplementary chart of dose reduction is provided. The doses included are the standard
      medication doses.

      Digoxin, diuretic, spironolactone will be discontinued if both the beta-blocker and ACE-ARB
      discontinuation has been well tolerated or if a clinical indication warrants the
      discontinuation. Up titration of therapies will not be permitted.

      Additional therapy for SBP > 130 or DBP >80mmHg with non-ACE or beta blocker therapy will be

      Genotyping: Genetic analysis for DCM causing gene will be sent for the study patients. The
      genotyping is selective, patient will have the option to opt out the genetic analysis if they
      do not prefer having a genotyping done. All samples will be stored in a bio bank to maximum
      of 25 years. Two comparisons will be conducted on the genotyping:

        1. The genetic typing for Patients with improved EF will be compared to the control group
           from the ongoing DCM cohort at the McGill University Health Center.

        2. A second comparison between the patients within the withdrawal cohort. A comparison will
           be made between patients with rebound HF and the patient who did not HF with
           discontinuation of medical therapy.

Study Type


Primary Outcome

Number of patients that become symptomatic

Secondary Outcome

 Number of patients that drop EF to <45%


Dilated Cardiomyopathy



Study Arms / Comparison Groups

Description:  Withdrawal of beta blockers and ACE inhibitors


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 19, 2016

Completion Date

November 2019

Primary Completion Date

August 24, 2017

Eligibility Criteria

        Inclusion Criteria:

          1. Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF < 40 % at

          2. DCM with recovered LV function to > or = to 50% documented on 2 ECHO examinations,
             with the most recent ECHO examination within 1 year of enrolment.

          3. Time from initial diagnosis of DCM more or equal to 24 month.

          4. Last hospitalization for decompensated HF > 1year.

        Exclusion criteria:

          1. Ischemic cardiomyopathy

          2. Other structural pathology such as: Hypertrophic cardiomyopathy, Valvular
             cardiomyopathy or congenital heart disease.

          3. Last hospitalization for decompensated HF < 1year ago.

          4. Previous sustained ventricle tachycardia or ventricle fibrillation (VF) arrest.




18 Years - N/A

Accepts Healthy Volunteers



Nadia Giannetti, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

McGill University


 McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Sponsor

Nadia Giannetti, MD, Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre

Verification Date

January 2020